Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma

Archives of Surgery

Volumn 147, Issue 8, 2012, Pages 753-760

  Gnerlich, Jennifer L ^a   Luka, Samuel R ^a   Deshpande, Anjali D ^b,c   Dubray, Bernard J ^a   Weir, Joshua S ^a   Carpenter, Danielle H ^b   Brunt, Elizabeth M ^b   Strasberg, Steven M ^a,c   Hawkins, William G ^a,c   Linehan, David C ^a,c  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ADENOCARCINOMA; AGED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; TREATMENT FAILURE;

EID: 84865586712     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2012.1126     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Tani M, Kawai M, Terasawa H, et al. Prognostic factors for long-term survival in patients with locally invasive pancreatic cancer. J Hepatobiliary Pancreat Surg. 2007;14(6):545-550. (Pubitemid 350201464)
3. Shimada K, Sakamoto Y, Sano T, Kosuge T, Hiraoka N. Reappraisal of the clinical significance of tumor size in patients with pancreatic ductal carcinoma. Pancreas. 2006;33(3):233-239. (Pubitemid 44470137)
4. Allison DC, Bose KK, Hruban RH, et al. Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy. Ann Surg. 1991;214(6):648-656.
5. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165(1):68-73. (Pubitemid 23289365)
6. Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol. 2000;73(4):212-218. (Pubitemid 30238413)
7. Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13(7):1337-1344.
8. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas: implications for radiation therapy. Ann Surg. 1993;217(2):144-148. (Pubitemid 23059285)
9. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving? Ann Surg. 1995;221(1):59-66.
10. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg. 1995;221(6):721-733.
11. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 1996;83(5):625-631. (Pubitemid 26163547)
12. Nishimura Y, Hosotani R, Shibamoto Y, et al. External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications. Int J Radiat Oncol Biol Phys. 1997;39(1):39-49. (Pubitemid 27396280)
13. Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg. 1999;65(7):618-624. (Pubitemid 29309912)
14. Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Mosella G. Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Chir Ital. 2000;52(3):263-270.
15. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas- 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567-579.
16. Neoptolemos JP, Stocken DD, Dunn JA, et al European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758-768. (Pubitemid 33117196)
17. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232-1237. (Pubitemid 44547022)
18. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52-60. (Pubitemid 47012207)
19. Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247(3):456-462.
20. Kato K, Yamada S, Sugimoto H, et al. Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: influence of resection margin status on survival. Pancreas. 2009;38(6):605-612.
21. Butturini G, Stocken DD, Wente MN, et al Pancreatic Cancer Meta-Analysis Group. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008;143(1):75-83. (Pubitemid 351159303)
22. Neoptolemos JP, Stocken DD, Friess H, et al European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-1210. (Pubitemid 38339364)
23. Neoptolemos JP, Stocken DD, Bassi C, et al European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073-1081.
24. Verbeke CS. Resection margins and R1 rates in pancreatic cancer: are we there yet? Histopathology. 2008;52(7):787-796. (Pubitemid 351724902)
25. Fatima J, Schnelldorfer T, Barton J, et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 2010;145(2):167-172.
26. Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15(6):1651-1660.
27. Westgaard A, Tafjord S, Farstad IN, et al. Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor. BMC Cancer. 2008;8:5.
28. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21(2):195-200. (Pubitemid 27053441)
29. Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990;66(1):56-61. (Pubitemid 20197085)
30. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009;35(6):600-604.
31. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973: analysis of surgical failure and implications for radiation therapy. Cancer. 1976;37(3):1519-1524.
32. Westerdahl J, Andrén-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer: local or hepatic? Hepatogastroenterology. 1993;40(4):384-387. (Pubitemid 23258561)
33. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72(7):2118-2123. (Pubitemid 23280135)
34. Hazard L, Tward JD, Szabo A, Shrieve DC. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer. 2007;110(10):2191-2201. (Pubitemid 350100740)
35. Garofalo MC, Kwok Y, Regine WF. The evolving role of postoperative adjuvant radiation therapy for pancreatic cancer. Surg Oncol Clin N Am. 2004;13(4):589-604, viii. (Pubitemid 39209342)
36. Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18(5):1319-1326.
37. Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol. 2008;26(21):3511-3516.
38. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26(21):3503-3510.
39. Ghaneh P, Neoptolemos JP. Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial of chemoradiotherapy and chemotherapy for pancreatic cancer. Surg Oncol Clin N Am. 2004;13(4):567-587, vii-viii. (Pubitemid 39209341)
40. Picozzi VJ, Pisters PW, Vickers SM, Strasberg SM. Strength of the evidence: adjuvant therapy for resected pancreatic cancer. J Gastrointest Surg. 2008;12(4):657-661.
41. Moertel CG, Frytak S, Hahn RG, et al Gastrointestinal Tumor Study Group. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-flourouracil), and high dose radiation + 5-flourouracil. Cancer. 1981;48(8):1705-1710. (Pubitemid 11022870)
42. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899-903. (Pubitemid 15040883)
43. Wilkowski R; Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59(12):2006-2010.
44. Campbell F, Smith RA, Whelan P, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009;55(3):277-283.
45. Crane CH, Varadhachary GR, Wolff RA, Fleming JB. Challenges in the study of adjuvant chemoradiation after pancreaticoduodenectomy. Ann Surg Oncol. 2010;17(4):950-952.
46. Katz MH, Merchant NB, Brower S, et al American College of Surgeons Oncology Group. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011;18(2):337-344.
47. Asiyanbola B, Gleisner A, Herman JM, et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg. 2009;13(4):752-759.
48. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27(3):324-329. (Pubitemid 36920145)
49. Pedrazzoli S, DiCarlo V, Dionigi R, et al Lymphadenectomy Study Group. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Ann Surg. 1998;228(4):508-517. (Pubitemid 30194394)